Nurix, Inc. is a science-minded, goal-oriented organization that is focused on bringing novel, first-in-class therapies to patients. Nurix is a leader in discovering a new class of drugs that work by modulating the protein degradation machinery of the cell. The Nurix scientific team has established an innovative drug discovery platform based on recent advances in understanding of the ubiquitin proteasome system (UPS). The UPS is a regulatory network that controls protein stabilization and degradation, a function vital to the healthy life of a cell, uncovering therapeutic opportunities in multiple disease areas.
Nurix’s Protein Regulation Platform enables the discovery of selective inhibitors or activators of the UPS, enabling the discovery of new class of drugs that can restore normal cellular homeostasis. In September 2015, Nurix entered into an exclusive collaboration with Celgene for the discovery and development of next-generation therapies targeting protein homeostasis in oncology, immunology and inflammation, including the rapidly evolving field of immuno-oncology.
Nurix was founded by internationally recognized experts in the ubiquitin proteasome field and is funded by leading life science investors, Third Rock Ventures and The Column Group. The company is headquartered in San Francisco, California
We are seeking a highly skilled and motivated in vivo pharmacologist to support Nurix’s mission of targeting E3 ubiquitin ligases in the areas of oncology and immunology. The ideal candidate will have expertise in small molecule PK/PD studies in oncology and/or inflammation. This individual will work closely with our drug discovery project scientists on late-stage lead optimization of novel compounds to evaluate PK/PD relationships, in vivo efficacy and ex vivo immune cell function. The candidate must be self-driven, organized, able to work well with project scientists, and able to thrive in an exciting environment in a rapidly-growing company.
• Ph.D. in pharmacology, immunology, cancer biology or related field with 8+ years of industry experience for Senior Scientist or 4+ years for Scientist II
• Expertise in small molecule drug development and PK/PD assay technologies
• Expertise with hit-to-lead optimization and establishment of PK/PD relationships
• Experience optimizing compounds with a variety of pharmacokinetic and metabolic profiles
• Experience managing preclinical toxicology studies and evaluating dosing regimens and formulations appropriate for early or late preclinical development
• In vivo pharmacology expertise with tumor or autoimmunity models preferred
• Writing preclinical reports or sections of IND a plus
• Proven ability to manage junior scientists, external collaborations, and CROs
• Excellent communication and presentation skills
• Excellent interpersonal skills and ability to work productively in a highly dynamic environment